NanoViricides Inc. (NNVC)

[DaysOnTheBeach]

The reason results in humans trials will likely be similar to those found in pre-clinicals in thousands of animals across multiple species rests in the manner of operation of NanoViricides' drugs.

Highly unusual relative to other types drugs, Viricides act totally independently of the animal's immune system. The Cides operate directly on the virus in the medium of the bloodstream. They attach to the virus particle in the bloodstream and physically rip it apart, harmlessly spilling it's contents. NanoViricides' drugs are specific to viral particles, while being agnostic as to host. There is therefore no anticipated scientific reason for human efficacy to be different from that demonstrated so overwhelmingly in pre-clinical animal studies.

Further, another potential for harm is avoided basis the fact that the Viricide drugs do not enter cells. They remain in the bloodstream. So, no interactions with species-specific structures.

So, we have our two factors. One, the drug's mechanism is likely to function perfectly as well in humans as it does in other animals because there's nothing specific to humans that's required for efficacy. And two, zero toxicity has been demonstrated in any animal tested in pre-clinicals, and there's no anticipated mechanism relative to humans which might cause an issue.

True, it will only be after the completion of human clinical trials that these statements are proven. However, appropriately so, share price currently reflects the pre-clinical status of the company's research. Huge share price appreciation will come as we get further down the road.


best to all.